Abstract: The present disclosure generally relates to personalized nutritional compositions for pediatric subjects, wherein the nutritional composition can include one of three distinct profiles of human milk oligosaccharides (HMOs). The present disclosure also relates to methods for determining the composition of HMOs present in or that would be present in the breast milk of the mother of a pediatric subject as determined by the mother's secretor status and/or Lewis blood group, and providing to the pediatric subject a nutritional composition comprising an HMO profile most similar to the HMOs present or that would be present in the breast milk of the subject's mother.

Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including galacto-oligosaccharide and human milk oligosaccharide or a precursor thereof. Further, the nutritional compositions may include GOS in combination with a first human milk oligosaccharide or precursor thereof and a second human milk oligosaccharide or precursor thereof. The disclosed nutritional compositions advantageously modify gut microbiome and improve select markers of immunity, brain structure, and gut function.

Abstract: The present disclosure generally relates to personalized nutritional compositions for pediatric subjects, wherein the nutritional composition can include one of three distinct profiles of human milk oligosaccharides (HMOs). The present disclosure also relates to methods for determining the composition of HMOs present in or that would be present in the breast milk of the mother of a pediatric subject as determined by the mother's secretor status and/or Lewis blood group, and providing to the pediatric subject a nutritional composition comprising an HMO profile most similar to the HMOs present or that would be present in the breast milk of the subject's mother.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including a human milk oligosaccharide or a precursor thereof. Further, the nutritional compositions may include a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. The disclosed nutritional compositions advantageously modify gut microbiome and improve select markers of immunity, brain structure, and gut function.

Abstract: A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition having up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source includes at least about 0.5 mg/100 kcal of milk or non-milk polar lipids; up to about 5 g/100 kcal of a protein source; at least about 15 mg/100 kcal of lactoferrin from a non-human source; about 0.015 g/100 kcal to about 0.15 g/100 kcal of a prebiotic composition including polydextrose and/or galactooligosaccharide; and at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids.

Abstract: The present disclosure a method and nutritional composition for improving the microbiome and metabolic profile of a pediatric subject, which includes administering to a pediatric subject a composition having up to about 7 g/100 kCal of a protein or protein equivalent source; up to about 7 g/100 kCal of a fat or lipid source; at least about 5 g/100 kCal of a carbohydrate; at least about 0.05 mg/100 kCal of bacterial metabolites; and either a probiotic or a prebiotic composition, or both.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. More particularly, the present disclosure relates to a nutritional composition having: (i) a protein source, (ii) a lipid source, (iii) a carbohydrate source, (iv) a human milk oligosaccharide or a precursor thereof, (v) polydextrose and/or galacto-oligosaccharides, and (vi) a probiotic. The disclosed nutritional compositions advantageously promote the gut-brain axis.

Abstract: The present disclosure generally relates to pediatric nutritional compositions including a prebiotic mixture of galacto-oligosaccharide and/or polydextrose, a probiotic, such as Lactobacillus rhamnosus GG, and human milk oligosaccharides. More particularly, the present disclosure relates to a nutritional composition having: (i) a protein source, (ii) a lipid source, (iii) a carbohydrate source, (iv) a human milk oligosaccharide or a precursor thereof, (v) polydextrose and/or galacto-oligosaccharides, and (vi) a probiotic. The disclosed nutritional compositions advantageously promote the gut-brain axis.

Abstract: The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes Lactobacillus rhamnosus GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.

Abstract: The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes Lactobacillus rhamnosus GG (LGG), galacto-oligosaccharide(s) (GOS) and polydextrose (PDX) to the subject. The combination of LGG, GOS, and PDX may exhibit additive or synergistic beneficial health effects when consumed. The nutritional compositions herein are suitable for administration to children and infants.

Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: Provided is a composition and method for modulating serotonergic receptor expression, reducing anxiety-like behavior and stress-induced inflammatory response in a pediatric subject, the method including administering to the pediatric subject a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides. Further provided is a method for reducing constipation in a pediatric subject by providing a nutritional composition including lactoferrin from a non-human source and a prebiotic composition including polydextrose and/or galactooligosaccharides.

Abstract: A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition having up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source includes at least about 0.5 mg/100 kcal of milk or non-milk polar lipids; up to about 5 g/100 kcal of a protein source; at least about 15 mg/100 kcal of lactoferrin from a non-human source; about 0.015 g/100 kcal to about 0.15 g/100 kcal of a prebiotic composition including polydextrose and/or galactooligosaccharide; and at least about 5 mg/100 kcal of a source of long chain polyunsaturated fatty acids.